Immunogenicitet I kliniske studier for svær sepsis er frekvensen af anti- human aktiveret protein C IgA/ IgG/ IgM antistoffer eller neutraliserende antistoffer lav hos voksne patienter og er omtrent ens for de testede drotrecogin alfa (aktiveret) - og placebobehandlede patienter.
Immunogenicity In adult patients in severe sepsis clinical studies, the frequency of anti-human Activated Protein C IgA/ IgG/ IgM antibodies or neutralizing antibodies is low and is similar between drotrecogin alfa (activated) and placebo-treated patients tested.